Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | CCR1 | P32246 | 3/20 | 0.41 |
| ▸ | CCR5 | P51681 | 3/20 | 0.41 |
| ▸ | CCR8 | P51685 | 3/20 | 0.41 |
| ▸ | METAP1 | P53582 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.41 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | CBFB | Q13951 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5328041 | 0.79 | KDM1A (0.51) | KDM1AKDM4ELMNACCR1CCR5 | |
| SCHEMBL31039988 | 0.78 | L3MBTL1 (0.42) | KDM1AKDM4ECCR1CCR5CCR8 | |
| SCHEMBL5845698 | 0.78 | GRM5 (0.51) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL4725122 | 0.77 | KDM4E (0.44) | KDM1AKDM4ELMNACCR1CCR5 | |
| SCHEMBL3925449 | 0.77 | NPSR1 (0.54) | KDM1AKDM4ELMNACYP1A2POLB | |
| SCHEMBL6856211 | 0.76 | ALDH1A1 (0.46) | KDM4EALDH1A1SMN1; SMN2RAB9ATDP1 | |
| SCHEMBL29901533 | 0.76 | CCR1 (0.52) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL28115227 | 0.76 | CCR1 (0.52) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL28723689 | 0.75 | KDM4E (0.59) | KDM1AKDM4ELMNACCR1CCR5 | |
| SCHEMBL12377643 | 0.75 | KDM4E (0.54) | KDM4ELMNACCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242970-B2 | Lactam derivatives useful as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-01-26 | — | — | US | disclosed |
| EP-2638008-B1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-07-01 | — | — | EP | disclosed |
| EP-2638008-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-20130237525-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-12 | — | — | US | disclosed |
| CN-103201261-A | Lactam derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD | 2013-07-10 | — | — | CN | disclosed |
| WO-2012063207-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237525-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | KDM1A 1270/4885KDM4E 2065/4885LMNA 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.